Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Doses Patients in China Trial of PD-L1 for Hepatitis B

publication date: Aug 17, 2020

Ascletis Pharma of Hangzhou has started dosing HBV patients in a China Phase IIa trial of its PD-L1 antibody. In 2019, Ascletis in-licensed China rights to the immunotherapy from Alphamab for patients with viral diseases. Alphamab, which continues to hold rights to the candidate for cancer, has tested the PD-L1 in more than 1,000 oncology patients. Ascletis agreed to pay Alphamab upfront and milestone payments, but it will be eligible to receive royalties on ex-China sales of the PD-L1 in viral diseases. More details....

Stock Symbol: (HK: 1672) (HK: 9966)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here